<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Bone and soft tissue sarcomas, tumors of the skin</journal-id><journal-title-group><journal-title xml:lang="en">Bone and soft tissue sarcomas, tumors of the skin</journal-title><trans-title-group xml:lang="ru"><trans-title>Саркомы костей, мягких тканей и опухоли кожи</trans-title></trans-title-group></journal-title-group><issn publication-format="print">2219-4614</issn><issn publication-format="electronic">2782-3687</issn><publisher><publisher-name xml:lang="en">Publishing House ABV Press</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">757</article-id><article-id pub-id-type="doi">10.17650/2219-4614-2026-18-1-72-78</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>REAL CLINICAL CASES</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>КЛИНИЧЕСКИЕ СЛУЧАИ</subject></subj-group><subj-group subj-group-type="article-type"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title xml:lang="en">Epithelioid sarcoma in a child: difficulties of diagnosis and experience of complex treatment</article-title><trans-title-group xml:lang="ru"><trans-title>Эпителиоидная саркома у ребенка: трудности диагностики и опыт комплексного лечения</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0009-0002-4796-8249</contrib-id><name-alternatives><name xml:lang="en"><surname>Gunyakov</surname><given-names>S. O.</given-names></name><name xml:lang="ru"><surname>Гуняков</surname><given-names>С. О.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><email>wordex2006@rambler.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-3888-9656</contrib-id><name-alternatives><name xml:lang="en"><surname>Inyushkina</surname><given-names>E. V.</given-names></name><name xml:lang="ru"><surname>Инюшкина</surname><given-names>Е. В.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><email>wordex2006@rambler.ru</email><xref ref-type="aff" rid="aff1"/><xref ref-type="aff" rid="aff2"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-7914-651X</contrib-id><name-alternatives><name xml:lang="en"><surname>Khizhnikov</surname><given-names>A. V.</given-names></name><name xml:lang="ru"><surname>Хижников</surname><given-names>А. В.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><email>wordex2006@rambler.ru</email><xref ref-type="aff" rid="aff1"/><xref ref-type="aff" rid="aff2"/><xref ref-type="aff" rid="aff3"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0009-0005-2500-5670</contrib-id><name-alternatives><name xml:lang="en"><surname>Stepanova</surname><given-names>V. O.</given-names></name><name xml:lang="ru"><surname>Степанова</surname><given-names>В. О.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><email>wordex2006@rambler.ru</email><xref ref-type="aff" rid="aff2"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-8398-7001</contrib-id><contrib-id contrib-id-type="spin">7652-0122</contrib-id><name-alternatives><name xml:lang="en"><surname>Rykov</surname><given-names>Maxim Yu.</given-names></name><name xml:lang="ru"><surname>Рыков</surname><given-names>Максим Юрьевич</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><email>wordex2006@rambler.ru</email><xref ref-type="aff" rid="aff3"/><xref ref-type="aff" rid="aff4"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">State Scientific Center of the Russian Federation – A.I. Burnazyan Federal Medical Biophysical Center, Russian Federal Medical and Biological Agency</institution></aff><aff><institution xml:lang="ru">ФГБУ «Государственный научный центр Российской Федерации – Федеральный медицинский биофизический центр им. А.И. Бурназяна»</institution></aff></aff-alternatives><aff-alternatives id="aff2"><aff><institution xml:lang="en">Moscow Regional Oncological Dispensary</institution></aff><aff><institution xml:lang="ru">ГБУЗ МО «Московский областной онкологический диспансер»</institution></aff></aff-alternatives><aff-alternatives id="aff3"><aff><institution xml:lang="en">Russian State Social University</institution></aff><aff><institution xml:lang="ru">ФГБОУ ВО «Российский государственный социальный университет»</institution></aff></aff-alternatives><aff-alternatives id="aff4"><aff><institution xml:lang="en">Russian Research Institute of Health, Ministry of Health of Russia</institution></aff><aff><institution xml:lang="ru">ФГБУ «Центральный научно-исследовательский институт информатизации и организации здравоохранения» Минздрава России</institution></aff></aff-alternatives><pub-date date-type="pub" iso-8601-date="2026-04-22" publication-format="electronic"><day>22</day><month>04</month><year>2026</year></pub-date><volume>18</volume><issue>1</issue><issue-title xml:lang="en"/><issue-title xml:lang="ru"/><fpage>72</fpage><lpage>78</lpage><history><date date-type="received" iso-8601-date="2025-09-27"><day>27</day><month>09</month><year>2025</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; 2026, ABV-Press</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; 2026, АБВ-пресс</copyright-statement><copyright-year>2026</copyright-year><copyright-holder xml:lang="en">ABV-Press</copyright-holder><copyright-holder xml:lang="ru">АБВ-пресс</copyright-holder><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/">https://creativecommons.org/licenses/by/4.0/</ali:license_ref></license></permissions><self-uri xlink:href="https://sarbon.abvpress.ru/jour/article/view/757">https://sarbon.abvpress.ru/jour/article/view/757</self-uri><abstract xml:lang="en"><p><bold>Introduction.</bold> Epithelioid sarcoma is a rare malignant tumor of the soft tissues developing mostly in young adults. In children this pathology is diagnosed very rarely which often leads to its late verification and unplanned surgical interventions aimed at tumor resection which at early stages is mistaken for a benign neoplasm. The main difficulties are associated with non-specificity of the clinical presentation and the necessity of using immunohistochemical and molecular methods for establishment of the final diagnosis.</p> <p>The article describes a clinical case of diagnosis and treatment of epithelioid soft tissue sarcoma in a child; difficulties of diagnosis associated with morphological verification and differential diagnosis of this tumor are presented, and efficacy of combination treatment consisting of radical surgical intervention and adjuvant radiotherapy is analyzed.</p> <p><bold>Clinical case. </bold>A boy, 11 years old, with epithelioid sarcoma of the soft tissues of the right shoulder. For diagnosis, medical history, clinical examination and instrumental methods – ultrasound, magnetic resonance tomography and computed tomography of the thoracic cage and abdomen, scintigraphy and positron emission tomography/computed tomography were used. Additionally, bone marrow biopsy to exclude systemic tumor advancement was performed. Treatment included radical surgical tumor resection with defect reconstruction and subsequent adjuvant radiotherapy at the tumor bed. Efficacy of the therapy was evaluated based on clinical data and results of dynamics in control examinations. No serious complications were reported, local control was achieved, as well as good quality of life of the child in short-term observation period.</p> <p><bold>Conclusion.</bold> The presented clinical case demonstrates difficulties of early diagnosis of epithelioid sarcoma in children, adds to the current clinical base, and has practical value for improvement of management of patients of pediatric age with rare tumors of the soft tissues.</p></abstract><trans-abstract xml:lang="ru"><p><bold>Введение.</bold> Эпителиоидная саркома относится к числу редких злокачественных опухолей мягких тканей, встречающихся преимущественно у молодых взрослых. В детском возрасте данная патология диагностируется крайне редко, что зачастую приводит к ее поздней верификации и выполнению неплановых хирургических вмешательств по удалению опухоли, которую на ранних стадиях принимают за доброкачественное новообразование. Основные трудности связаны с неспецифичностью клинической картины и необходимостью применения иммуногистохимических и молекулярных методов для установления окончательного диагноза.</p> <p>В статье описан клинический случай диагностики и лечения эпителиоидной саркомы мягких тканей у ребенка, представлены трудности в установлении диагноза, связанные с морфологической верификацией и дифференциальной диагностикой этой опухоли, а также проанализирована эффективность комплексного лечения, включающего радикальное хирургическое вмешательство и адъювантную лучевую терапию.</p> <p><bold>Клинический случай.</bold> Мальчик, 11 лет, с эпителиоидной саркомой мягких тканей правого плеча. Для установления диагноза использованы данные анамнеза, клинического осмотра и результаты инструментальных методов – ультразвукового исследования, магнитно-резонансной томографии и компьютерной томографии грудной клетки и брюшной полости, сцинтиграфия и позитронная эмиссионная томография, совмещенная с компьютерной томографией. Дополнительно выполнена пункция костного мозга для исключения системного распространения опухоли. Лечение включало радикальное хирургическое иссечение опухоли с реконструкцией дефекта и последующую адъювантную лучевую терапию на область ее ложа. Оценка эффективности терапии проводилась на основе клинических данных и результатов контрольных обследований в динамике. Серьезных осложнений выявлено не было, удалось добиться локального контроля над заболеванием и сохранить хорошее качество жизни ребенка в ближайшем периоде наблюдения.</p> <p><bold>Заключение.</bold> Представленный клинический случай иллюстрирует трудности ранней диагностики эпителиоидной саркомы у детей, дополняет существующую клиническую базу и имеет практическую ценность для совершенствования подходов к ведению пациентов детского возраста с редкими опухолями мягких тканей.</p></trans-abstract><kwd-group xml:lang="en"><kwd>pediatric oncology</kwd><kwd>pediatric surgery</kwd><kwd>radiation therapy</kwd><kwd>epithelioid sarcoma</kwd><kwd>soft tissue sarcoma</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>детская онкология</kwd><kwd>детская хирургия</kwd><kwd>лучевая терапия</kwd><kwd>эпителиоидная саркома</kwd><kwd>саркома мягких тканей</kwd></kwd-group><funding-group/></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><mixed-citation>Gounder M., Schöffski P., Jones R.L. et al. Tazemetostat in advanced epithelioid sarcoma with loss of INI1/SMARCB1. Lancet Oncol 2020;21(11):1423–32. DOI: 10.1016/S1470-2045(20)30451-4</mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation>Del Savio E., Maestro R. Recent insights into the pathobiology of epithelioid sarcoma. Cells 2022;11(17):2626. DOI: 10.3390/cells11172626</mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation>Grünewald T.G.P., Jones R.L., Judson I. et al. Epithelioid sarcoma: translational aspects and future perspectives. Clin Cancer Res 2024;30(6):1079–92. DOI: 10.1158/1078-0432.CCR-23-3073</mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation>Basile G., Le Péchoux C., Terrier P. et al. Curability of patients with lymph node metastases from soft tissue sarcoma. Cancer 2020;126(19):4334–44. DOI: 10.1002/cncr.33189</mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation>Liu Q.-K., He Z.-Q., Jiang N. et al. Risk factors for lymph node metastasis of soft tissue sarcomas. J Orthop Surg Res 2022;17(1):167. DOI: 10.1186/s13018-022-03050-3</mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation>Carter C.S., Patel R.M. Cutaneous soft tissue tumors: diagnostically disorienting epithelioid tumors that are not epithelial, and other perplexing mesenchymal lesions. Mod Pathol 2020;33(1):66–82. DOI: 10.1038/s41379-019-0387-5</mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation>Andrei V., Haefliger S., Baumhoer D. Superficial mesenchymal tumours expressing epithelial markers on immunohistochemistry: diagnostic clues and pitfalls. Semin Diagn Pathol 2023;40(4):238–45. DOI: 10.1053/j.semdp.2023.04.016</mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation>Talbot J.H., Hidalgo D.A., Vu M.M. et al. Epithelioid sarcoma in a young child: a case report and review of the literature. Plast Reconstr Surg Global Open 2021;9(2):e3377. DOI: 10.1097/GOX.0000000000003377</mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation>Zhang R., Liu J., Liu L. et al. Delayed diagnosis of pediatric intra-articular epithelioid sarcoma: a case report and literature review. BMC Pediatr 2023;23(1):488. DOI: 10.1186/s12887-023-04305-6</mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation>Dermawan J.K., Singer S., Tap W.D. et al. The genetic landscape of SMARCB1 alterations in SMARCB1-deficient spectrum of mesenchymal neoplasms. Mod Pathol 2022;35(12):1900–9. DOI: 10.1038/s41379-022-01148-x</mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation>Gronchi A., Miah A.B., Dei Tos A.P. et al. Soft tissue and visceral sarcomas: ESMO-EURACAN-GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2021;32(11):1348–65. DOI: 10.1016/j.annonc.2021.07.006</mixed-citation></ref><ref id="B12"><label>12.</label><mixed-citation>Hayes A.J., Strauss D.C., Jones R. L. et al. UK guidelines for the management of soft tissue sarcomas. Br J Cancer 2025;132(1):11–31. DOI: 10.1038/s41416-024-02674-y</mixed-citation></ref><ref id="B13"><label>13.</label><mixed-citation>De Juan Ferré A., Álvarez Álvarez R., Casado Herráez A. et al. SEOM Clinical Guideline of management of soft-tissue sarcoma (2020). Clin Transl Oncol 2021;23(5):922–30. DOI: 10.1007/s12094-020-02534-0</mixed-citation></ref><ref id="B14"><label>14.</label><mixed-citation>Radiopaedia. Epithelioid sarcoma – reference article. 2025. Available at: https://radiopaedia.org/articles/epithelioid-sarcoma</mixed-citation></ref><ref id="B15"><label>15.</label><mixed-citation>Tan Y.-L., Wang L., Li Z. et al. Epithelioid sarcoma of the spine: a review of literature and case report. J Clin Med 2023;12(17):5632. DOI: 10.3390/jcm12175632</mixed-citation></ref><ref id="B16"><label>16.</label><mixed-citation>U.S. Food and Drug Administration. FDA approves tazemetostat for advanced epithelioid sarcoma. FDA, 2020.</mixed-citation></ref><ref id="B17"><label>17.</label><mixed-citation>Straining R., Eighmy W. Tazemetostat: EZH2 inhibitor. J Adv Pract Oncol 2022;13(2):158–63. DOI: 10.6004/jadpro.2022.13.2.7</mixed-citation></ref><ref id="B18"><label>18.</label><mixed-citation>Oncology (CancerNetwork). Three things you should know about identifying and treating epithelioid sarcoma. Oncology 2025;39(1):34–6.</mixed-citation></ref><ref id="B19"><label>19.</label><mixed-citation>National Cancer Institute. Childhood Soft Tissue Sarcoma Treatment (PDQ®): Health Professional Version. Bethesda (MD): NCI, 2025.</mixed-citation></ref><ref id="B20"><label>20.</label><mixed-citation>Blay J.-Y., Le Cesne A., Ray-Coquard I. et al. SELNET clinical practice guidelines for soft tissue sarcoma. Cancer Treat Rev 2022;102:102312. DOI: 10.1016/j.ctrv.2022.102312</mixed-citation></ref><ref id="B21"><label>21.</label><mixed-citation>Needs T., Fillman E.P. Epithelioid sarcoma. StatPearls. Treasure Island (FL): StatPearls Publishing, 2024.</mixed-citation></ref><ref id="B22"><label>22.</label><mixed-citation>Xing Y.M., Pan Z.Y., Li Y.W. et al. [Diagnosis and treatment of epithelioid sarcoma]. Zhonghua Zhong Liu Za Zhi 2011;33(11):872–4. (In Chinese).</mixed-citation></ref><ref id="B23"><label>23.</label><mixed-citation>Casanova M., Ferrari A., Bisogno G. et al. Epithelioid sarcoma in children and adolescents: a report from the Italian and German Soft Tissue Sarcoma Cooperative Groups. Cancer 2021;127(4):600–8. DOI: 10.1002/cncr.33255</mixed-citation></ref><ref id="B24"><label>24.</label><mixed-citation>Ferrari A., de Salvo G.L., Bisogno G. et al. Radiation therapy in pediatric non-rhabdomyosarcoma soft tissue sarcomas: lessons from the European Cooperative Study. Pediatric Blood Cancer 2020;67(9):e28478. DOI: 10.1002/pbc.28478</mixed-citation></ref><ref id="B25"><label>25.</label><mixed-citation>Albertsmeier M., Rauch A., Roeder F. et al. External beam radiation therapy for resectable soft tissue sarcoma: a systematic review and meta-analysis. Ann Surg Oncol 2018;25(3):754–67. DOI: 10.1245/s10434-017-6081-2</mixed-citation></ref><ref id="B26"><label>26.</label><mixed-citation>Ferrari A., Brennan B., Casanova M. et al. Pediatric Non-rhabdomyosarcoma soft tissue sarcomas: standard of care and treatment recommendations from the European Paediatric Soft Tissue Sarcoma Study Group (EpSSG). Cancer Manag Res 2022;14:2885–902. DOI: 10.2147/CMAR.S368381</mixed-citation></ref><ref id="B27"><label>27.</label><mixed-citation>Kim A., Dome J.S., Meany H.J. Chemotherapy and multidisciplinary approaches to pediatric sarcomas. In: Sarcoma. Ed. by R. Henshaw. Springer, Cham, 2017.</mixed-citation></ref><ref id="B28"><label>28.</label><mixed-citation>Van der Graaf W.T., Gelderblom H. New systemic therapy options for advanced sarcomas. Curr Treat Options Oncol 2012;13(3):306–17. DOI: 10.1007/s11864-012-0196-2</mixed-citation></ref><ref id="B29"><label>29.</label><mixed-citation>Simeone N., Frezza A.M., Zaffaroni N., Stacchiotti S. Tazemetostat for advanced epithelioid sarcoma: current status and future perspectives. Future Oncol 2021;17(10):1253–63. DOI: 10.2217/fon-2020-0781</mixed-citation></ref><ref id="B30"><label>30.</label><mixed-citation>Italiano A., Soria J.C., Toulmonde M. et al. Tazemetostat, an EZH2 inhibitor, in relapsed or refractory B-cell non-Hodgkin lymphoma and advanced solid tumours: a first-in-human, open-label, phase 1 study. Lancet Oncol 2018;19(5):649–59. DOI: 10.1016/S1470-2045(18)30145-1</mixed-citation></ref><ref id="B31"><label>31.</label><mixed-citation>Lautz T.B., Hayes-Jordan A. Recent progress in pediatric soft tissue sarcoma therapy. Semin Pediatr Surg 2019;28(6):150862. DOI: 10.1016/j.sempedsurg.2019.150862</mixed-citation></ref><ref id="B32"><label>32.</label><mixed-citation>Cesne A.L., Bauer S., Demetri G.D. et al. Safety and efficacy of pazopanib in advanced soft tissue sarcoma: PALETTE (EORTC 62072) subgroup analyses. BMC Cancer 2019;19(1):794. DOI: 10.1186/s12885-019-5988-3</mixed-citation></ref><ref id="B33"><label>33.</label><mixed-citation>Jones R.L., Constantinidou A., Olmos D. et al. Role of palliative chemotherapy in advanced epithelioid sarcoma. Am J Clin Oncol 2012;35(4):351–7. DOI: 10.1097/COC.0b013e3182118cf7</mixed-citation></ref><ref id="B34"><label>34.</label><mixed-citation>Shelmerdine S.C., Chavhan G.B., Babyn P.S. et al. Imaging of late complications of cancer therapy in children. Pediatr Radiol 2017;47(3):254–66. DOI: 10.1007/s00247-016-3708-6</mixed-citation></ref><ref id="B35"><label>35.</label><mixed-citation>Nguyen V.X., Nguyen B.D. Proximal-type epithelioid sarcoma of the scrotum: 18F-FDG PET/CT imaging. Clin Nucl Med 2013;38(1):e45–7. DOI: 10.1097/RLU.0b013e31824853db</mixed-citation></ref></ref-list></back></article>
